GlobeNewswire Inc | Jun 24, 2021 08:00AM EDT

June 24, 2021

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandlers Virtual EASL Takeaway Day on Monday, June 28, at10:00 a.m. EDT.

An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireos website, ir.albireopharma.com, for at least two weeks following the event.

About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireos lead product candidate, Bylvay, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 trials in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA recently granted Priority Review and set a PDUFA goal date of July 20, 2021. In Europe, the EMAs CHMP recently issued a positive opinion and Bylvay is the only IBATi granted accelerated assessment by the EMA. Bylvay has been provisionally accepted by both the FDA and EMA as the brand name for odevixibat. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:Colleen Alabiso, 857-356-3905,colleen.alabiso@albireopharma.comLisa Rivero, 617-947-0899,lisa.rivero@syneoshealth.com

Investor Contact:Hans Vitzthum,LifeSci Advisors, LLC., 617-430-7578